Citius Pharmaceuticals (NASDAQ:CTXR) Trading 1.4% Higher

Citius Pharmaceuticals, Inc. (NASDAQ:CTXRGet Rating)’s share price traded up 1.4% during mid-day trading on Monday . The stock traded as high as $1.40 and last traded at $1.40. 1,936,226 shares traded hands during mid-day trading, an increase of 48% from the average session volume of 1,306,067 shares. The stock had previously closed at $1.38.

Citius Pharmaceuticals Trading Down 0.8 %

The company has a market capitalization of $172.53 million, a PE ratio of -5.41 and a beta of 1.21. The firm’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.10.

Citius Pharmaceuticals (NASDAQ:CTXRGet Rating) last released its quarterly earnings data on Thursday, December 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). As a group, analysts anticipate that Citius Pharmaceuticals, Inc. will post 0.43 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Citius Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 6,216,638 shares of the company’s stock worth $11,128,000 after purchasing an additional 40,028 shares during the period. Millennium Management LLC purchased a new stake in shares of Citius Pharmaceuticals in the 2nd quarter worth approximately $1,601,000. Northern Trust Corp lifted its position in shares of Citius Pharmaceuticals by 6.4% in the 1st quarter. Northern Trust Corp now owns 1,063,417 shares of the company’s stock worth $1,904,000 after purchasing an additional 63,552 shares during the period. Renaissance Technologies LLC lifted its position in shares of Citius Pharmaceuticals by 2.7% in the 3rd quarter. Renaissance Technologies LLC now owns 390,770 shares of the company’s stock worth $473,000 after purchasing an additional 10,300 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Citius Pharmaceuticals by 4.5% in the 1st quarter. Bank of New York Mellon Corp now owns 379,314 shares of the company’s stock worth $679,000 after purchasing an additional 16,213 shares during the period. Hedge funds and other institutional investors own 9.38% of the company’s stock.

About Citius Pharmaceuticals

(Get Rating)

Citius Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite.

See Also

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.